^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tuvusertib (M1774)

    i
    Company:
    EMD Serono
    Drug class:
    ATR inhibitor
    Related drugs:
    Apply
    Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (DDRiver Solid Tumours 301) (NCT04170153)
    Phase 1
    EMD Serono Research & Development Institute, Inc.
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/20/2019
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    ARID1A • ATRX
    |
    ATM mutation • ARID1A mutation
    |
    Zejula (niraparib) • tuvusertib (M1774)
    Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors (NCT05687136)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/07/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2026
    ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18
    |
    ATM mutation • ARID1A mutation
    |
    peposertib (M3814) • tuvusertib (M1774)
    Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031) (NCT05950464)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/18/2023
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer (NCT05828082)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    10/16/2023
    Primary completion :
    04/25/2025
    Completion :
    04/25/2025
    SPOP • RAC1 • FDFT1 • MVD
    |
    SPOP mutation
    |
    tuvusertib (M1774)
    I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) (NCT05986071)
    Phase 1/2
    Institut Paoli-Calmettes
    Not yet recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/01/2024
    Primary completion :
    04/01/2027
    Completion :
    10/15/2027
    HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1
    |
    HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation
    |
    fulvestrant • tuvusertib (M1774)